ArticleInvestigative ophthalmology & visual science2025
Protective Effects of Estradiol on Disease Progression in a Murine Model of Fuchs Endothelial Corneal Dystrophy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to investigate the protective effects of estradiol (E2) on disease progression in Fuchs endothelial corneal dystrophy (FECD) and to explore potential underlying mechanisms. Methods: E2-supplemented drinking water was administered to Col8a2Q455K/Q455K mice, a mouse model of FECD. The corneal endothelial phenotype was evaluated using contact specular microscopy. In vitro studies were performed using immortalized FECD (iFECD) cells derived from patients with and without TCF4 triplet repeat expansion to assess the effects of E2 on extracellular matrix (ECM) production and protein aggregation through immunofluorescence, whereas transforming growth factor-beta (TGF-β) signaling and epithelial-mesenchymal transition (EMT)-related factors were evaluated by Western blot analysis. Results: E2 treatment significantly reduced guttae formation (0.55 ± 0.23% vs. 0.97 ± 0.22%, P < 0.001) and maintained higher endothelial cell density (2263 ± 177 vs. 2058 ± 118 cells/mm², P = 0.004) in FECD mice compared with untreated controls at 20 weeks of age. In vitro studies demonstrated that E2 suppressed TGF-β2-induced upregulation of ECM proteins (fibronectin, biglycan, and collagen I) and reduced protein aggregation in both iFECD cell lines. Mechanistically, E2 inhibited TGF-β signaling by suppressing Smad2/3 phosphorylation and downregulating EMT-related factors (Snail and ZEB1). Conclusions: E2 ameliorates FECD progression by suppressing excessive ECM production. Our in vitro data suggest this protective effect is mediated through the inhibition of the TGF-β-Smad signaling pathway. These findings provide critical in vivo evidence for the therapeutic potential of E2, establishing a strong rationale for its clinical investigation as a novel treatment for FECD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.